Cipher Pharmaceuticals Inc.
TSX:CPH.TODrug Manufacturers - Specialty & Generic
+$0.15 today
- Market cap
- $331.67M
- Beta
- 0.48
- P/E (TTM)
- 9.3
- EPS (TTM)
- $1.22
Volume 0.04M
Average 0.03M
CPH.TO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Cipher Pharmaceuticals Inc.TSX: CPH.TO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $6.16M rose 134.9% year over year, behind the +236.1% change in trailing-twelve-month net income. Sequentially, it fell 54.4% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.
Context
- Net income amounted to 53.2% of revenue in FY2025, up 18.6 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of $25.2M (-7.8%) for the fiscal year ending Dec 2026, a slowdown from the +136.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.16M-54.4% QoQ
- Last fiscal yearDec 2025
- $27.33M+136.7% YoY
- LTMMar 2026
- $31.07M+236.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +134.9% | -9.2% | -144.1 pp |
| 1 year | +136.7% | -7.8% | -144.5 pp |
| 3-year CAGR | +0.9% | -9.8% | -10.7 pp |
| 5-year CAGR | -3.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 27.33M USD
- Year-over-year change
- +136.7%
- 4-year CAGR
- +37.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.33M | +136.7% |
| FY2024 | 2024-12-31 | 11.55M | -43.4% |
| FY2023 | 2023-12-31 | 20.38M | -23.5% |
| FY2022 | 2022-12-31 | 26.64M | +243.3% |
| FY2021 | 2021-12-31 | 7.76M | — |
Net Income vs competitors
How CPH.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +236.1% is the highest of 8, against a peer median of -56.4%.
- Net income amounts to 61.0% of revenue for CPH.TO, versus a peer median of 15.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$263.55M CAD | -56.4% | -28.6% | 84.8% | |
| LTM Mar 2026 | CA$50.24M CAD | -418.7% | -39.5% | 15.8% | |
| LTM Mar 2026 | CA$38.02M CAD | +59.5% | +61.8% | 1377.1% | |
| LTM Mar 2026 | $31.07M USD | +236.1% | +0.9% | 61.0% | |
| LTM Mar 2026 | CA$25.21M CAD | -249.3% | — | 9.2% | |
| LTM Mar 2026 | $20.19M USD | -71.2% | — | 7.7% | |
| LTM Mar 2026 | $8.81M USD | -39.0% | -25.7% | 17.2% | |
| LTM Mar 2026 | CA$5.61M CAD | -49.3% | -43.6% | 1.1% | |
| Peer median (excluding CPH.TO) | — | -56.4% | -28.6% | 15.8% | |
Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.76M | 26.64M | 20.38M | 11.55M | 27.33M |
| Depreciation & Amortization | 701K | 989K | 1.23M | 4.02M | 7.23M |
| Deferred Income Tax | (114K) | (14.31M) | (2.74M) | (8.64M) | (10.36M) |
| Stock-Based Compensation | 139K | 403K | 1.19M | 1.07M | 1.74M |
| Change in Working Capital | 4.68M | (3.03M) | (3.28M) | 8.95M | 5.32M |
| Accounts Receivables | 2.56M | (144K) | 1.71M | (8.77M) | 2.7M |
| Inventory | (758K) | (502K) | (830K) | 3.6M | (2.44M) |
| Accounts Payables | (1.23M) | (1.45M) | 532K | 1.28M | 527.07K |
| Other Working Capital | 4.11M | (940K) | (4.69M) | 12.85M | 4.53M |
| Other Non-Cash Items | 652K | (109K) | (788K) | 2.6M | (1.01M) |
| Operating Cash Flow | 13.81M | 10.58M | 16M | 19.55M | 30.25M |
| Capital Expenditures | 0 | (81K) | (144K) | (44K) | (28.49K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 132.28K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (123K) | (80M) | 0 |
| Investing Cash Flow | 0 | (81K) | (144K) | (80.04M) | (72.24K) |
| Debt Repayment | (828K) | (56K) | (111K) | 39.79M | (35.61M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 218.76K |
| Common Stock Repurchased | (1.72M) | (1.99M) | (5.56M) | (176K) | (5.48M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 75K | 132K | 426K | (317K) | (311.36K) |
| Financing Cash Flow | (2.47M) | (1.91M) | (5.24M) | 39.3M | (41.18M) |
| Effect of Forex Changes | 62K | (292K) | 378K | (786K) | (194.92K) |
| Net Change in Cash | 11.41M | 8.29M | 10.99M | (21.99M) | (11.2M) |
| Free Cash Flow | 13.81M | 10.49M | 15.98M | 19.5M | 30.22M |
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
Intrinsic Alpha fair value
Locked
Current Price
$13.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.